Kim JA - Search Results

1

Determinants of survival following hepatic resection for metastatic colorectal cancer.

Bakalakos EA, Kim JA, Young DC, Martin EW Jr. Bakalakos EA, et al. Among authors: kim ja. World J Surg. 1998 Apr;22(4):399-404; discussion 404-5. doi: 10.1007/s002689900404. World J Surg. 1998. PMID: 9523523

2

Pilot study evaluating the intraoperative localization of radiolabeled monoclonal antibody CC83 in patients with metastatic colorectal carcinoma.

Burak WE Jr, Schneebaum S, Kim JA, Arnold MW, Hinkle G, Berens A, Mojzisik C, Martin EW Jr. Burak WE Jr, et al. Among authors: kim ja. Surgery. 1995 Jul;118(1):103-8. doi: 10.1016/s0039-6060(05)80016-9. Surgery. 1995. PMID: 7604370

3

Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer.

Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Triozzi PL, et al. Among authors: kim ja. Cancer. 2000 Dec 15;89(12):2646-54. doi: 10.1002/1097-0142(20001215)89:12<2646::aid-cncr18>3.0.co;2-a. Cancer. 2000. PMID: 11135227 Clinical Trial.

4

Modulation of CD4 cell cytokine production by colon cancer-associated mucin.

Kim JA, Dayton MA, Aldrich W, Triozzi PL. Kim JA, et al. Cancer Immunol Immunother. 1999 Dec;48(9):525-32. doi: 10.1007/s002620050601. Cancer Immunol Immunother. 1999. PMID: 10602890

5

Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer.

Burak WE Jr, Walker MJ, Yee LD, Kim JA, Saha S, Hinkle G, Olsen JO, Pozderac R, Farrar WB. Burak WE Jr, et al. Among authors: kim ja. Am J Surg. 1999 Jun;177(6):445-9. doi: 10.1016/s0002-9610(99)00088-4. Am J Surg. 1999. PMID: 10414690 Clinical Trial.

6

Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.

Kim JA, Bresler HS, Martin EW Jr, Aldrich W, Heffelfinger M, Triozzi PL. Kim JA, et al. Cancer. 1999 Jul 1;86(1):22-30. Cancer. 1999. PMID: 10391559 Clinical Trial.

7

Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer.

Rucker R, Bresler HS, Heffelfinger M, Kim JA, Martin EW Jr, Triozzi PL. Rucker R, et al. Among authors: kim ja. J Immunother. 1999 Jan;22(1):80-4. doi: 10.1097/00002371-199901000-00011. J Immunother. 1999. PMID: 9924703 Clinical Trial.

8

Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy.

Doran T, Stuhlmiller H, Kim JA, Martin EW Jr, Triozzi PL. Doran T, et al. Among authors: kim ja. J Immunother. 1997 Sep;20(5):372-6. doi: 10.1097/00002371-199709000-00006. J Immunother. 1997. PMID: 9336744

9

Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal cancer.

Triozzi PL, Kim JA, Martin EW Jr, Colcher D, Heffelfinger M, Rucker R. Triozzi PL, et al. Among authors: kim ja. Hybridoma. 1997 Apr;16(2):147-51. doi: 10.1089/hyb.1997.16.147. Hybridoma. 1997. PMID: 9145316 Clinical Trial.

10

Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide.

Fisher WE, Muscarella P, O'Dorisio TM, O'Dorisio MS, Kim JA, Doran TA, Sabourin CL, Schirmer WJ. Fisher WE, et al. Among authors: kim ja. Surgery. 1996 Aug;120(2):234-40; discussion 240-1. doi: 10.1016/s0039-6060(96)80293-5. Surgery. 1996. PMID: 8751588

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results